Jaime Xinos
ACHIEVE LIFE SCIENCESAbout Jaime Xinos
Jaime Xinos is Chief Commercial Officer (CCO) of Achieve Life Sciences (ACHV), promoted in October 2024 after serving as EVP, Commercial since September 2017 . She has nearly 25 years of commercial experience at OncoGenex, Pfizer, Novartis, and Abbott; she holds a BA and MBA from the University of Illinois . As an executive officer (age 48 as of April 15, 2025), Xinos leads pre-launch strategy for cytisinicline (availability, access, awareness), including a digital-first, AI-enabled go-to-market platform and a premium-pricing thesis versus generic varenicline . Company-level performance context disclosed in ACHV’s pay-versus-performance shows 2024 TSR value of $100 invested at 43.46, alongside a 2024 net loss of $39.8M; these are company metrics, not specific to Xinos .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Achieve Life Sciences | Chief Commercial Officer | Oct 2024–present | Leads commercialization planning for cytisinicline; pillars: availability (3PL, trade/distribution), access (payer strategy, preapproval exchange), awareness (data-driven targeting); digital-first, AI-enabled launch roadmap and Omnicom partnership . |
| Achieve Life Sciences | EVP, Commercial | Sep 2017–Oct 2024 | Built commercial strategy pre-CCO; progressed market access groundwork and provider/patient engagement plans . |
| OncoGenex Pharmaceuticals | VP, Marketing & Corporate Communications; Sr Director, Global Oncology Commercial Development | n/d | Senior commercial leadership roles prior to Achieve . |
| Pfizer; Novartis; Abbott Laboratories | Various commercial roles in marketing, commercial development, and sales | n/d | Big pharma commercial training across functions; informs specialty product go-to-market execution . |
n/d = not disclosed in cited filings .
External Roles
No public-company board or external directorships disclosed for Xinos in the 2025 proxy; section lists executive officers and biographies without external board roles for her .
Fixed Compensation
- Not disclosed. Xinos was not a named executive officer (NEO) in the 2025 proxy’s executive compensation section, which covers CEO, CMO/President, CFO, and former CEO . The October 2024 CCO promotion press release did not include compensation terms .
Performance Compensation
- Not disclosed specific to Xinos. The 2025 proxy details PSU/option structures for NEOs tied to regulatory milestones (e.g., NDA acceptance/approval) but does not enumerate Xinos’s grants or metrics .
Equity Ownership & Alignment
- Beneficial ownership: Xinos is not listed individually in the beneficial ownership table; the table covers 5% holders, directors, NEOs, and officers as a group .
- Hedging/pledging: ACHV’s Insider Trading Policy prohibits hedging, short sales, and using or pledging company stock as collateral without pre-clearance; effectively restricts pledging and hedging by employees and directors .
- Clawback: A Compensation Recovery Policy adopted in Aug 2023 enables recoupment of incentive-based compensation from current and former officers upon an accounting restatement, administered by the Compensation Committee .
Employment Terms
- No CCO employment agreement or severance/change-of-control terms for Xinos were disclosed in the 2025 proxy or related 8-Ks reviewed; Item 5.02 filings in 2024–2025 addressed CEO/CFO/CMO changes, not CCO terms .
Performance Compensation – Structure Context (Company-Level, NEOs)
While not specific to Xinos, ACHV’s incentive design for NEOs (context for pay-for-performance culture) included regulatorily anchored PSUs and options:
- PSU triggers included NDA acceptance (Day-74 letter) and FDA approval/acquisition milestones; options generally vest over time; sizing targeted median to 75th percentile vs peers to emphasize at-risk pay for a pre-revenue biotech .
Commercial Execution Highlights under Xinos
| Area | Detail | Evidence |
|---|---|---|
| Launch pillars | Availability (3PL contracted; state licensure underway), Access (payer research, pricing/contracting strategy; preapproval information exchange), Awareness (data-driven targeting of motivated patients and high-volume prescribers) | |
| Data/AI strategy | Building AI-enabled, omnichannel platform with Omnicom; digital-first approach to optimize targeting, content, and ROI | |
| Pricing view | Intends to price as branded at a premium to generic varenicline (Chantix) based on differentiation and payer feedback | |
| Field timing | Preapproval payer engagement to begin in Q4; outsourced account managers targeted for Q1 next year (relative to Aug 2025 call) | |
| Launch readiness cadence | Company of ACHV’s size may need time post-approval to get drug into channel; aiming for strong launch near approval timing |
Risk Indicators & Governance Safeguards (Company-Level)
- Hedging/pledging restrictions as alignment safeguard .
- Clawback policy covering incentive-based compensation upon restatement .
- Related-party transactions: none beyond disclosed director/NEO compensation and capital markets events in the related-party section .
Investment Implications
- Commercial leadership credibility: Xinos is architecting a modern, data-driven launch with premium pricing intent and early payer engagement—key levers for uptake and gross-to-net in a cost-conscious category .
- Alignment levers: While her individual equity/ownership and severance terms aren’t disclosed, firm-wide hedging/pledging prohibitions and a clawback policy mitigate misalignment risk; lack of disclosed CCO-specific economics modestly elevates uncertainty around personal retention incentives .
- Execution risk and timing: ACHV anticipates logistical and access ramp post-approval; the reliance on outsourced/partnered capabilities can accelerate scale but introduces dependency risk; investor monitoring should focus on payer coverage wins, time-to-fill metrics, and channel readiness milestones through approval .